This summer, Station Houston is connecting the dots for student and alumni entrepreneurs within Houston's innovation ecosystem. Station Houston/Facebook

Houston universities — namely the University of Houston and Rice University — have been providing student and alumni entrepreneurs with acceleration programming for some time now through RED Labs and OwlSpark, respectively. But nonprofit acceleration hub Station Houston is connecting the dots with these programs — and inviting more schools to join in — through a new summer acceleration program.

"One of the things we haven't historically had in Houston that other cities have are broad collaborations between our universities to help build on one another's resources and really demonstrate for our young people — the talent that we want to keep here — exactly how deep and strong the opportunity to be in Houston is," Gabriella Rowe, CEO of Station, tells InnovationMap.

The program will bring in 30 to 40 student and alumni from academic partners, which currently includes Rice, UH, and the University of St. Thomas, to Station. The schools will be responsible for selecting their participants and some of their own programming, and Station will provide additional resources, events, and full member access.

"We're not just going to depend on them bumping into someone at the coffee pot," Rowe says. "We're going to do meet and greets, some speed dating events, and some pitch practice events, so that they have the opportunity to have experienced entrepreneurs give them feedback and share their experiences."

The program, which is free to its participants, has derived out of planning for the Rice University's upcoming innovation district hub called The Ion, for which Station is the programming partner. Launching the student and alumni summer program ahead of The Ion's debut allows Station to get a couple summer cohorts under its belt.

"We have been for a number of months now — and will continue for the next two years — built out out a hub where all of the things that can be happening in The Ion," Rowe says. "We're piloting an building here first, so that, when the building opens, it can open in full force."

The plan is also to collect more universities in the area for the program and even expand it to provide more student and alumni access to resources.

"We have the ability at Station to give an expanding base as more schools choose to join them over time, so that hopefully we end up with something that is really robust in its ability to support students all year round — not just as a summer program," Rowe says.

Combining the forces of Houston's universities is unprecedented, Rowe says, but crucial to ensuring that these young entrepreneurs aren't leaving Houston for other major cities unaware of what their city has out there for them.

"For me, more than anything, it's about exposing these young, motivated entrepreneurs to all of the resources available in Houston," Rowe says. "By bringing them here into Station, we have the ability to show them first hand what entrepreneurs in Houston have access to. It allows them to see what an incredible place Houston is to stay and build and grow your company."

The Ion is expected to debut in 2021. Courtesy of Rice University

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”